Clinical Trial Update: Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating inclisiran as monotherapy in Chinese adults with elevated LDL-C and low-to-moderate ASCVD risk shows efficacy and safety results; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Hypercholesterolemia or Mixed Dyslipidemia | Phase 3 | Status: COMPLETED | Results posted: 2025-04-20